Common genetic variants in pre-microRNAs are associated with cervical cancer susceptibility in southern Chinese women
© The author(s)..
Cervical cancer is a commonly diagnosed cancer among females. Polymorphisms in pre-microRNAs have been demonstrated to play critical roles in cancer. However, the roles of pre-microRNA polymorphisms in the aetiology of cervical cancer have not been well documented. We genotyped eight pre-microRNA polymorphisms in 290 cervical cancer patients and 445 cancer-free female controls using quantitative polymerase chain reaction with TaqMan probes. To estimate the association between pre-microRNA polymorphisms and the risk of cervical cancer, an unconditional logistic regression model was used to calculate the odds ratio (OR) and 95% confidence interval (CI), adjusting for age, menopause, delivery, and abortion. We found that the pre-miR-137 rs1625579 T > G polymorphism was associated with a significant decrease in cervical cancer risk (TG/GG versus TT: adjusted OR (AOR) = 0.47, 95% CI = 0.27-0.81; TG versus TT: AOR = 0.56, 95% CI = 0.34-0.91). We also observed a significant association between the pre-miR-27a rs895819 T > C polymorphism and decreased cervical cancer risk (TC/CC versus TT: AOR = 0.65, 95% CI = 0.44-0.96). Stratified analysis further demonstrated that the pre-miR-137 rs1625579 T > C and pre-miR-27a rs895819 T > C polymorphisms significantly reduced the risk of cervical cancer susceptibility in patients younger than 49 years, those who experienced fewer abortions, and clinical stage I patients. Moreover, the pre-miR-137 rs1625579 T > G polymorphism showed protective effects in premenopausal women, squamous cell carcinoma patients, and patients with unclassified types of pathologies; the pre-miR-27a rs895819 T > C polymorphism was also associated with a decreased risk in patients older than 49 years, menopausal women, and women who had experienced vaginal pregnancies. The pre-miR-137 rs1625579 T > G and pre-miR-27a rs895819 T > C polymorphisms may provide protective effects against susceptibility to cervical cancer risk.
| Errataetall: |
CommentIn: J Cancer. 2020 Aug 28;11(21):6286-6287. - PMID 33033512 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of Cancer - 11(2020), 8 vom: 19., Seite 2133-2138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Guange [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case-control study |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection CommentIn: J Cancer. 2020 Aug 28;11(21):6286-6287. - PMID 33033512 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7150/jca.39636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307192792 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307192792 | ||
| 003 | DE-627 | ||
| 005 | 20231225125023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7150/jca.39636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1023.xml |
| 035 | |a (DE-627)NLM307192792 | ||
| 035 | |a (NLM)32127940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Guange |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Common genetic variants in pre-microRNAs are associated with cervical cancer susceptibility in southern Chinese women |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a CommentIn: J Cancer. 2020 Aug 28;11(21):6286-6287. - PMID 33033512 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The author(s). | ||
| 520 | |a Cervical cancer is a commonly diagnosed cancer among females. Polymorphisms in pre-microRNAs have been demonstrated to play critical roles in cancer. However, the roles of pre-microRNA polymorphisms in the aetiology of cervical cancer have not been well documented. We genotyped eight pre-microRNA polymorphisms in 290 cervical cancer patients and 445 cancer-free female controls using quantitative polymerase chain reaction with TaqMan probes. To estimate the association between pre-microRNA polymorphisms and the risk of cervical cancer, an unconditional logistic regression model was used to calculate the odds ratio (OR) and 95% confidence interval (CI), adjusting for age, menopause, delivery, and abortion. We found that the pre-miR-137 rs1625579 T > G polymorphism was associated with a significant decrease in cervical cancer risk (TG/GG versus TT: adjusted OR (AOR) = 0.47, 95% CI = 0.27-0.81; TG versus TT: AOR = 0.56, 95% CI = 0.34-0.91). We also observed a significant association between the pre-miR-27a rs895819 T > C polymorphism and decreased cervical cancer risk (TC/CC versus TT: AOR = 0.65, 95% CI = 0.44-0.96). Stratified analysis further demonstrated that the pre-miR-137 rs1625579 T > C and pre-miR-27a rs895819 T > C polymorphisms significantly reduced the risk of cervical cancer susceptibility in patients younger than 49 years, those who experienced fewer abortions, and clinical stage I patients. Moreover, the pre-miR-137 rs1625579 T > G polymorphism showed protective effects in premenopausal women, squamous cell carcinoma patients, and patients with unclassified types of pathologies; the pre-miR-27a rs895819 T > C polymorphism was also associated with a decreased risk in patients older than 49 years, menopausal women, and women who had experienced vaginal pregnancies. The pre-miR-137 rs1625579 T > G and pre-miR-27a rs895819 T > C polymorphisms may provide protective effects against susceptibility to cervical cancer risk | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a case-control study | |
| 650 | 4 | |a cervical cancer | |
| 650 | 4 | |a genetic susceptibility | |
| 650 | 4 | |a polymorphism | |
| 650 | 4 | |a pre-microRNA | |
| 700 | 1 | |a Zhang, Mingyao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jiawei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Danyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Anqi |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Wenfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Cancer |d 2010 |g 11(2020), 8 vom: 19., Seite 2133-2138 |w (DE-627)NLM201575388 |x 1837-9664 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:8 |g day:19 |g pages:2133-2138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7150/jca.39636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 8 |b 19 |h 2133-2138 | ||